Cingulate to Participate in Benzinga All Live Access Event

Rhea-AI Summary

Cingulate Inc. (NASDAQ: CING) announced that Chairman and CEO Shane J. Schaffer will speak at the Benzinga All Access event on August 19, 2022, at 9 a.m. CST. The discussion will focus on unmet needs in Attention Deficit/Hyperactivity Disorder (ADHD) and the expansion of Cingulate’s Precision Timed Release™ (PTR™) platform into anxiety treatment. The event can be viewed live on Benzinga’s YouTube channel and on Cingulate’s investor website.

Cingulate is dedicated to improving treatment outcomes for patients through innovative drug delivery technology.

KANSAS CITY, Kan., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. Schaffer will participate in a live Benzinga All Access event on August 19, 2022, at 9 a.m. CST.

The discussion will address the current unmet needs in Attention Deficit/Hyperactivity Disorder (ADHD), as well as the expansion of Cingulate’s PTR platform into the anxiety therapeutic area. Dr. Schaffer will also provide a company overview.

The event may be viewed live on Benzinga’s YouTube channel, Benzinga All Access, and will also be available for viewing on Cingulate’s website at cingulate.com/investors.

About Cingulate^® 
Cingulate Inc. (NASDAQ: CING), is a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product candidates, including to treat anxiety disorders.

Cingulate is headquartered in Kansas City. For more information visit Cingulate.com

Investor Relations 
Thomas Dalton 
Head of Investor & Public Relations, Cingulate
TDalton@cingulate.com
913-942-2301

Matt Kreps
Darrow Associates
mkreps@darrowir.com
214-597-8200

Media Relations
Melyssa Weible
Elixir Health Public Relations
mweible@elixirhealthpr.com
201-723-5805

FAQ

When is the Cingulate Inc. event featuring Shane J. Schaffer?

The event is on August 19, 2022, at 9 a.m. CST.

What will be discussed during the Benzinga event for Cingulate Inc.?

The discussion will cover unmet needs in ADHD and the expansion into anxiety treatments.

Where can I watch the Cingulate Inc. event on August 19, 2022?

The event will be livestreamed on Benzinga’s YouTube channel and Cingulate’s investor website.

What is Cingulate Inc.'s focus in drug development?

Cingulate focuses on developing treatments for ADHD and expanding into anxiety disorders using its PTR technology.

What does PTR technology refer to in Cingulate Inc.'s context?

PTR stands for Precision Timed Release™, a proprietary drug delivery platform for optimizing treatment outcomes.